Abstract 5678
Background
Hepatocellular carcinoma (HCC) has relatively sensitive and specific serum tumor antigen markers (AFP), which is also the most common serological marker for cancer screening. However, there are unignorable limitations, including possible false-negatives/positives owing to confounding conditions. Reliable non-invasive diagnostics is still in urgent need. This work proposes a novel LDI-TOF-MS technique for HCC screening and diagnosis. By taking advantage of 3D nanostructures and machine learning, our technique enables high fidelity and reproducibility.
Methods
An LDI-TOF-MS platform was established for HCC screening and was applied to 139 patients with liver cancer, as well as 203 healthy controls (Table). All mass spectrum was collected within a mass range of 100 to 1,100 Da for metabolites. Based on the data acquired by LDI-TOF-MS, SVM algorithm was developed and applied for automated cancer classification across six cancer types, which was further validated by single blinded samples with randomly selected cancer patients and controls.Table: 1432P
Summary of patient and healthy control characteristics
Patient Type | N | Gender | Gender | Age | AJCC Stage | AJCC Stage | AJCC Stage | AJCC Stage |
---|---|---|---|---|---|---|---|---|
M(%) | F(%) | I | II | III | IV | |||
HCC | 139 | 120 (86.33%) | 19 (13.67%) | 55.63± 11.22(25-80) | 51 | 48 | 40 | - |
HC | 203 | 117 (57.64%) | 86 (42.36%) | 47.68± 10.78(23-76) | - | - | - | - |
Results
This assay demonstrated an average sensitivity of 96% and a specificity over 98% in detecting HCC. In our cohort, 47 of 137 HCC patients (35.77%) were AFP negative (AFP<20ng/ml, stage I n = 18, stage II n = 17 and stage III n = 12). Here, we showed that the LDI-TOF-MS recognized almost all AFP-negative HCC. The sensitivity and specificity were obviously superior to AFP in HCC: only 2 of 137 HCCs (1.46%) were misclassified as healthy controls. In contrast, AFP positive and AFP negative HCCs were not readily distinguished by this method. Therefore, this method was independent of tumor markers.
Conclusions
This work established a low-cost, high-throughput procedure based on trace amount of serum to identify HCC as well as healthy controls with superior precision, making it a promising technique for clinical cancer research and translation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhongshan Hospital, Fudan University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2436 - Development and Validation of an RNA-Seq Assay for Gene Fusions Detection in Formalin-Fixed Paraffin-Embedded Samples
Presenter: Hua Dong
Session: Poster Display session 3
Resources:
Abstract
5271 - A Pilot Study to Implement an Artificial Intelligence (AI) System for Gastrointestinal Cancer Clinical Trial Matching
Presenter: Zhaohui Jin
Session: Poster Display session 3
Resources:
Abstract
4787 - A Blinded Comparison of Patient Treatments to Therapeutic Options Presented by an Artificial Intelligence-based Clinical Decision-support system
Presenter: Suthida Suwanvecho
Session: Poster Display session 3
Resources:
Abstract
5744 - OncOS: scalable and accurate next-generation sequencing analytics for precision oncology and personalized patient care
Presenter: Joe Thompson
Session: Poster Display session 3
Resources:
Abstract
3752 - The association between wearable device physical activity metrics and performance status in oncology: a systematic review
Presenter: Milan Kos
Session: Poster Display session 3
Resources:
Abstract
5820 - SomaticNET: neural network evaluation of somatic mutations in cancer
Presenter: Geoffroy Dubourg-Felonneau
Session: Poster Display session 3
Resources:
Abstract
4771 - Is there a role for Next-generation sequencing (NGS) profiling on metastatic non-colorectal gastrointestinal carcinomas (MNCGIC) in developing countries? A single center experience.
Presenter: Mauricio Ribeiro
Session: Poster Display session 3
Resources:
Abstract
1209 - Metastatic Cancer Whole-Exome Sequencing in daily practice
Presenter: Manon Réda
Session: Poster Display session 3
Resources:
Abstract
5702 - Genomic-Guided Individualized Precision Therapy in Refractory Metastatic Solid Tumor Patients with Extensively Poor Performance Status: A Chinese single institutional prospective observational real-world study
Presenter: Haitao Wang
Session: Poster Display session 3
Resources:
Abstract
4021 - Prospective pathological experience with research biopsies in the context of clinical trials at Vall d’Hebron Institute of Oncology
Presenter: Paolo Nuciforo
Session: Poster Display session 3
Resources:
Abstract